Published on: 
Supplements and Featured Publications, Express Report - Optimizing Blood Pressure Control in Clinical Practice, Volume 11, Issue 1 Express

George L. Bakris, MD

Professor, Departments of

Preventive and Internal Medicine

Vice Chairman

Department of Preventive Medicine

Rush University Medical Center

Chicago, IL

Björn Dahlöf, MD, PhD

Professor of Medicine

Göteborg University

Sahlgrenska University




Barry J. Materson, MD

Professor of Medicine

University of Miami School of


Miami, FL

Robert A. Phillips, MD, PhD

Chairman, Department of Medicine

Lenox Hill Hospital

Professor of Medicine

NYU School of Medicine

New York, NY

Sponsored by the University of Cincinnati College of Medicine for 1 Category 1 CME credit.

Release Date: February 2005

Expiration Date: February 28, 2006

To receive complimentary CME credit, take the quiz online at

Click on On-line/Self Study CME

The American Journal of Managed Care

Click on Express Report/Blood PressureFebruary 2005

For a hard copy of the test and evaluation, please call University of Cincinnati CME Department at 513-558-7350.

Educational Objectives

Upon completion of this continuing medical education (CME) activity, the reader should be able to:

  • Explain the rationale for using combination therapy to control blood pressure and prevent target-organdamage
  • Review effective antihypertensive therapy options for specific patient populations, including AfricanAmericans and patients with renal disease or diabetes
  • Discuss the role of combination therapy as first-line treatment of hypertension.

Credit Designation

The University of Cincinnati College of Medicine designates this educational activity for a maximum of one (1)Category 1 CME credit toward the AMA Physician's Recognition Award. Each physician should claim only thosehours that he/she actually spends in the educational activity. The University of Cincinnati College of Medicine is accreditedby the Accreditation Council for Continuing Medical Education (ACCME) to sponsor CME for physicians.

Disclosure Information

Consultant and Speaker's Bureau

Research Support

Consultant and

Speaker's Bureau

In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support,the presenters for this activity have completed conflict of interest disclosure statements. The following relationshipshave been disclosed: Dr Bakris: : AstraZeneca, Abbott, Amersham, Alteon, Biovail,Boehringer-Ingelheim, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Merck, Novartis, Sankyo, Sanofi, Solvay;: AstraZeneca, Abbott, Alteon, Amersham, Boehringer-Ingelheim, Forest, GlaxoSmithKline,Merck, Novartis, Sankyo, Solvay. Dr Dahlöf: Not available at time of printing. Dr Materson: : Novartis. Dr Phillips: Reported no commercial support.

Target Audience

This activity is intended for pharmacists, pharmacy directors, physicians, medical directors, pharmacy and therapeuticscommittee members, public health officials, and other managed care decision makers.

Publisher's Note

The American

Journal of Managed Care

This supplement was supported by an educational grant from Novartis Pharmaceuticals Corporation. The opinionsexpressed herein are not attributable to the supporter or to the publisher, editor, or editorial board of . Clinical judgment must guide each physician in weighing the benefits of treatment againstthe risk of toxicity. References made herein may indicate use of drugs at dosages, for periods of time, and in combinationsnot included in the current prescribing information. The amlodipine besylate/benazepril HCl combinationis manufactured by Novartis Pharmaceuticals Corporation, the commercial supporter of this activity.